Algorithm And Batterjee Pharma Partner To Localise Pharmaceuticals In Saudi Arabia

Algorithm, a major pharmaceutical company in the region, has formed a strategic alliance with Saudi Arabia's Batterjee Pharma. This partnership, marking a first for a Lebanese company, will localise Algorithm's product range within the Kingdom. The agreement involves the production and supply of several products that are licensed in both the EU and Japan.

The initial phase of this collaboration will focus on medications for critical conditions such as hyperlipidemia, dyslipidemia, and hypertension. By mid-2026, a complete technology transfer is expected. This effort aligns with Saudi Arabia's Vision 2030 and the Health Sector Transformation Program, aiming to bolster healthcare infrastructure, lessen dependence on imported medications, and elevate treatment standards.

Nabil Ghorayeb, Algorithm’s Human Health and Manufacturing Director, remarked, "KSA Localization Project is a bold milestone in Algorithm's journey – a testimony to our pioneering leadership. In partnership with Batterjee Pharma, we are localizing the manufacturing of highly differentiated therapies that address significant unmet medical needs – expediting access to innovation where it's needed most."

This project is not solely about localisation; it serves as a regional model for impactful innovation. It is designed to support Saudi Arabia's Vision 2030 while promoting sustainable economic growth through knowledge transfer. The initiative is expected to enhance healthcare resilience and set a precedent for the future of healthcare in the MENA region.

Dr. Mohamed Mazen Batterjee, CEO of Batterjee Pharma, highlighted the significance of this collaboration. "This collaboration is about impact: ensuring the uninterrupted supply of essential medicines for patients, creating valuable job opportunities, and driving higher local content in line with national priorities. Together with Algorithm, we are not only enhancing healthcare access today but also laying the foundation for a resilient and sustainable pharmaceutical sector in the region."